Chiasma (NASDAQ:CHMA) had its price target upped by research analysts at Piper Sandler from to in a report issued on Tuesday, The Fly reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock.

Other research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Chiasma from a “buy” rating to a “hold” rating in a research report on Monday, October 14th. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Chiasma in a research report on Thursday, November 7th. Finally, ValuEngine raised shares of Chiasma from a “sell” rating to a “hold” rating in a research report on Saturday, January 4th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Chiasma has an average rating of “Buy” and an average price target of $12.42.

Chiasma stock traded up $0.43 on Tuesday, reaching $5.17. 659,700 shares of the stock were exchanged, compared to its average volume of 512,056. The stock has a market cap of $199.18 million, a PE ratio of -4.04 and a beta of 1.16. Chiasma has a twelve month low of $3.20 and a twelve month high of $9.25. The firm has a fifty day moving average price of $5.19 and a two-hundred day moving average price of $5.45.

Chiasma (NASDAQ:CHMA) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.01. Equities analysts anticipate that Chiasma will post -1.03 EPS for the current fiscal year.

In other news, Director Roni Mamluk sold 61,139 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $5.51, for a total transaction of $336,875.89. Following the completion of the transaction, the director now owns 61,139 shares of the company’s stock, valued at $336,875.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.30% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Voya Investment Management LLC raised its position in shares of Chiasma by 20.3% during the third quarter. Voya Investment Management LLC now owns 12,713 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 2,149 shares during the last quarter. Rhumbline Advisers grew its stake in Chiasma by 11.4% during the third quarter. Rhumbline Advisers now owns 22,218 shares of the biotechnology company’s stock worth $110,000 after buying an additional 2,265 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in Chiasma by 35.4% during the second quarter. Cubist Systematic Strategies LLC now owns 14,235 shares of the biotechnology company’s stock worth $106,000 after buying an additional 3,722 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in Chiasma during the third quarter worth about $53,000. Finally, Tower Research Capital LLC TRC grew its stake in Chiasma by 461.4% during the third quarter. Tower Research Capital LLC TRC now owns 14,938 shares of the biotechnology company’s stock worth $74,000 after buying an additional 12,277 shares during the last quarter. 74.45% of the stock is owned by institutional investors and hedge funds.

Chiasma Company Profile

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Recommended Story: What is the Nikkei 225 index?    

The Fly

Analyst Recommendations for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.